Drug intelligence / Profile preview

99mTc-C02

Development stage
Preclinical
Lead developer
First Affiliated Hospital of Chongqing Medical University
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

99mTc-C02 is a technetium-99m (99mTc) radiolabeled derivative of the CXCR4 antagonist AMD070 (mavorixafor). It was developed by researchers at The First Affiliated Hospital of Chongqing Medical University as a novel molecular probe for single-photon emission computed tomography (SPECT) imaging of C-X-C chemokine receptor type 4 (CXCR4) expression. In preclinical evaluations, 99mTc-C02 demonstrated high and specific uptake in CXCR4-expressing cells, including Jurkat T-cell lymphoma and 4T1 breast cancer cells, as well as favorable tumor-to-background ratios in 4T1 xenograft-bearing mice. It represents a potential SPECT-based alternative to PET-based CXCR4 imaging agents like 68Ga-Pentixafor.

Other names
99mTc-labeled AMD070 derivative C02
02

Identity

Drug type
Radiopharmaceuticals
Modality
Small MoleculesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesGamma Emitters
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
breast cancer and precursor lesionsPreclinicalActive
hematologic lymphomasPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • First Affiliated Hospital of Chongqing Medical UniversityLead developer
07

Competitive landscape

Drugs on the same target
49
Drugs in the lead indication
1,053

Lead indication: breast cancer and precursor lesions

Most advanced in the lead indication

  1. cyclophosphamideApproved
  2. epirubicinApproved
  3. eribulinApproved
  4. fludeoxyglucose f 18Approved
  5. fluorouracilApproved

Beyond the preview

Go deeper on 99mTc-C02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-C02.

Work on 99mTc-C02? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call